PL355292A1 - Nowe kombinacje terapeutyczne zawierające(S)-2(benzylo-amino-metylo)-2,3,8,9-tetrahydro-7H-1,4-dioksyno[2,3-e] indol-8-on i neuroleptyki przeznaczonedo leczenia lub zapobiegania zaburzeniom psychotycznym - Google Patents

Nowe kombinacje terapeutyczne zawierające(S)-2(benzylo-amino-metylo)-2,3,8,9-tetrahydro-7H-1,4-dioksyno[2,3-e] indol-8-on i neuroleptyki przeznaczonedo leczenia lub zapobiegania zaburzeniom psychotycznym

Info

Publication number
PL355292A1
PL355292A1 PL00355292A PL35529200A PL355292A1 PL 355292 A1 PL355292 A1 PL 355292A1 PL 00355292 A PL00355292 A PL 00355292A PL 35529200 A PL35529200 A PL 35529200A PL 355292 A1 PL355292 A1 PL 355292A1
Authority
PL
Poland
Prior art keywords
combinations
dioxino
neuroleptics
benzylamino
indol
Prior art date
Application number
PL00355292A
Other languages
English (en)
Inventor
Karen Lovell Marquis
Original Assignee
Wyeth
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth filed Critical Wyeth
Publication of PL355292A1 publication Critical patent/PL355292A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL00355292A 1999-12-10 2000-12-07 Nowe kombinacje terapeutyczne zawierające(S)-2(benzylo-amino-metylo)-2,3,8,9-tetrahydro-7H-1,4-dioksyno[2,3-e] indol-8-on i neuroleptyki przeznaczonedo leczenia lub zapobiegania zaburzeniom psychotycznym PL355292A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US45860799A 1999-12-10 1999-12-10

Publications (1)

Publication Number Publication Date
PL355292A1 true PL355292A1 (pl) 2004-04-05

Family

ID=23821437

Family Applications (1)

Application Number Title Priority Date Filing Date
PL00355292A PL355292A1 (pl) 1999-12-10 2000-12-07 Nowe kombinacje terapeutyczne zawierające(S)-2(benzylo-amino-metylo)-2,3,8,9-tetrahydro-7H-1,4-dioksyno[2,3-e] indol-8-on i neuroleptyki przeznaczonedo leczenia lub zapobiegania zaburzeniom psychotycznym

Country Status (20)

Country Link
EP (1) EP1235570A2 (pl)
JP (1) JP5557409B2 (pl)
KR (1) KR100772854B1 (pl)
CN (1) CN1230164C (pl)
AR (1) AR026756A1 (pl)
AU (1) AU784211B2 (pl)
BR (1) BR0016168A (pl)
CA (1) CA2396351C (pl)
CZ (1) CZ20021880A3 (pl)
EA (1) EA005002B1 (pl)
HK (1) HK1045942A1 (pl)
HU (1) HUP0203309A3 (pl)
IL (2) IL149669A0 (pl)
MX (1) MXPA02005649A (pl)
NO (1) NO20022739L (pl)
NZ (1) NZ519381A (pl)
PL (1) PL355292A1 (pl)
TW (1) TWI222864B (pl)
WO (1) WO2001041750A2 (pl)
ZA (1) ZA200205484B (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050095292A1 (en) 2003-10-29 2005-05-05 Wyeth Sustained release pharmaceutical compositions
AU2006214233A1 (en) 2005-02-17 2006-08-24 Wyeth Cycloalkylfused indole, benzothiophene, benzofuran and indene derivatives
EP2633868A1 (en) * 2008-02-13 2013-09-04 Targacept, Inc. Combination of alpha 7 nicotinic agonists and antipsychotics
ES2925982T3 (es) * 2020-05-04 2022-10-20 Bioprojet Pharma Utilización de agonistas parciales D3 de dopamina para el tratamiento de trastornos del sistema nervioso central
GB202014184D0 (en) 2020-09-09 2020-10-21 Johnson Matthey Plc Modifed catalyst supports and catalysts supported thereon

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2987484B2 (ja) * 1995-03-16 1999-12-06 大塚製薬 株式会社 カルボスチリル誘導体の製造方法
US5756532A (en) * 1995-11-06 1998-05-26 American Home Products Corporation Aminomethyl-2 3 8 9-tetrahydro-7H-1 4-dioxino 2 3-E!-indol-8-ones and derivatives
GB9627005D0 (en) * 1996-12-27 1997-02-12 Knoll Ag Therapeutic agents

Also Published As

Publication number Publication date
TWI222864B (en) 2004-11-01
IL149669A (en) 2006-06-11
AR026756A1 (es) 2003-02-26
EA005002B1 (ru) 2004-10-28
HUP0203309A3 (en) 2004-12-28
CZ20021880A3 (cs) 2002-08-14
NO20022739D0 (no) 2002-06-07
EP1235570A2 (en) 2002-09-04
CN1409633A (zh) 2003-04-09
WO2001041750A3 (en) 2002-02-14
CN1230164C (zh) 2005-12-07
JP2003516350A (ja) 2003-05-13
MXPA02005649A (es) 2004-09-10
KR20030016207A (ko) 2003-02-26
AU1949001A (en) 2001-06-18
WO2001041750A2 (en) 2001-06-14
BR0016168A (pt) 2002-08-20
EA200200656A1 (ru) 2002-12-26
IL149669A0 (en) 2002-11-10
NO20022739L (no) 2002-06-07
HK1045942A1 (zh) 2002-12-20
NZ519381A (en) 2004-04-30
JP5557409B2 (ja) 2014-07-23
AU784211B2 (en) 2006-02-23
CA2396351C (en) 2009-11-10
CA2396351A1 (en) 2001-06-14
KR100772854B1 (ko) 2007-11-02
HUP0203309A2 (hu) 2003-01-28
ZA200205484B (en) 2003-12-31

Similar Documents

Publication Publication Date Title
IL267381A (en) A pharmaceutical preparation containing dextromethorphan and quinidine for the treatment of nervous disorders
TWI265808B (en) Valdecoxib compositions
EP1259240B8 (en) Agents, such as nicotinamide or cadpr for the treatment of skin disorders
MY127980A (en) A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders
IL152659A (en) Liquid pharmaceutical compositions comprising a pegylated human erythropoietin protein and a multiple charged inorganic anion, in a pharmaceutically acceptable buffer
HUP0104795A3 (en) Azabicycloalkanes as ccr5 modulators, pharmaceutical compositions comprising thereof and their use
FI956014A0 (fi) Nona- ja dekapeptidien käyttö lääkkeen valmistamiseksi AIDS-sairauden hoitoon
YU60900A (sh) Novi kristalni oblici antivirusnog benzimidazolskog jedinjenja
AU2001266152A1 (en) Novel substituted nitrocatechols, their use in the treatment of some central andperipheral nervous system disorders and pharmaceutical compositions containing them
MXPA02004701A (es) Sales de hidroxieicosatetraenoato, composiciones y metodos de uso para tratar trastornos de resequedad en los ojos.
IL140588A0 (en) Therapeutic composition based on flavonoids intended to be used in the treatment of tumours by cytotoxic agents
PL355292A1 (pl) Nowe kombinacje terapeutyczne zawierające(S)-2(benzylo-amino-metylo)-2,3,8,9-tetrahydro-7H-1,4-dioksyno[2,3-e] indol-8-on i neuroleptyki przeznaczonedo leczenia lub zapobiegania zaburzeniom psychotycznym
TW374085B (en) Novel piperidine derivatives, their preparation, pharmaceutical formulation and medical use
AP2000001946A0 (en) Form V1 5,6-Dichloro-2-(isopropylamino)-1-(B-L-Ribofuranosyl)-1H- benzimidazole.
SE0001916D0 (sv) Novel formulation
JO2199B1 (en) Replaced pyrrols
BG104914A (en) Paroxetine maleate
WO2004006887A3 (en) Composition and methods for the treatment of skin disorders
AU3992897A (en) Use of sulbutiamine to obtain pharmaceutical compositions useful in the treatment of certain psychomotor and psycho-intellectual disorders
AU2002357691A1 (en) Methods and compositions to treat pain and painful disorders using 577, 20739 or 57145

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)